Optimizing Stress Ulcer Prophylaxis Practices and Reducing Associated Costs in Intensive Care Units: a Nonrandomized Controlled Study

NCT06586333 | Completed

• 1 other identifier: 2023/181
• Study Type: interventional
• Target: 196
• Locations: 1 country
• Sites: 1

Brief Summary

The study is a prospectively designed, nonrandomized controlled study. It was conducted for six months at the EICU and GICU of a training and research hospital between 1 Jun 2023 and 1 December 2023.

Conditions

Stress Ulcer

Keywords

guidelines; adherence; stress ulcer; intensive care

Outcome Measures

Primary Outcomes (1)

• Adherence rates to ASHP guidelines

  % of physician who adhere to ASHP guidelines

  6 months

Secondary Outcomes (1)

• Cost saving

  6 months

Study Arms (2)

Control Group

NO INTERVENTION

Involved GICU patients as the standard care services observation group (OG). Stress ulcer prophylaxis were only observed and no intervention done

Intervention

EXPERIMENTAL

In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP stress ulcer prophylaxis guidelines

Drug: stress ulcer prophylaxis

Interventions

stress ulcer prophylaxis DRUG

In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines

Also known as: clinical pharmacist

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• Patients with a history of stomach cancer, admission to the ICU because of GI bleeding, subtotal/total gastrectomy, or receiving a proton pump inhibitor for therapeutic purposes were excluded from the study.

Sponsors & Collaborators

• Altinbas University: lead

Study Sites (1)

Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinical Pharmacy, İstanbul, Türkiye,

Istanbul, Turkey, 34147, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Duodenal Ulcer

Interventions

Pharmacists

Condition Hierarchy (Ancestors)

Peptic Ulcer; Duodenal Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Health Personnel; Health Care Facilities Workforce and Services

Study Officials

• yunus emre Ayhan, Specialist clinical pharmacy

  Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinical Pharmacy, İstanbul, Türkiye,

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc.Professor

Model Details: Study Design and Participants The study is a prospectively designed, nonrandomized controlled study. It was conducted for six months at the EICU and GICU of a training and research hospital between 1 Jun 2023 and 1 December 2023. The study involved GICU patients as the standard care services observation group (OG). The use of SUP in the GICU was only monitored and noted. In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines \[1\]. The study duration was six months concurrently in the EICU and the GICU. Before inclusion, written informed consent was obtained from each patient or their parent(s)/legal guardian(s). Subjects with incomplete data were excluded. The inclusion criteria were patients aged ≥18 years and hospitalized for ≥24 hours in the EICU/GICU. Patients with a history of stomach cancer, admission to the ICU because of GI bleeding, subtotal/tot

Study Record Dates

• First Submitted: September 4, 2024
• First Posted: September 19, 2024
• Study Start: June 1, 2023
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: September 19, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)